The COVID-19 vaccine developed by US biotech Novavax (Nasdaq: NVAX) and its partner the Serum Institute of India (SII) has been granted a regulatory approval for the first time.
The National Agency of Drug and Food Control of the Republic of Indonesia has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based vaccine with Matrix-M adjuvant. It will be manufactured by SII in India and marketed by SII in Indonesia under the brand name Covovax.
Shares in Novavax closed 16% higher on Monday, when the approval was announced.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze